PharmaSpotter
SearchVendors
HomeSearchIQVIA Vigilance Platform
IQVIA logo

IQVIA Vigilance Platform

by IQVIA
Visit Product Website
PharmacovigilancePharmacovigilancePharma Edition Available

A modular, multi-tenant SaaS pharmacovigilance platform that handles end-to-end safety case lifecycle (intake → case processing → submission → signal detection → periodic reporting) for biopharma, vaccine, and medical-device safety teams. IQVIA pairs the software with a global services bench (3,000+ safety professionals in 100+ countries) and embedded AI/NLP automation in the Vigilance Detect and Vigilance Intake modules.

IQVIA Vigilance Platform is IQVIA's safety database, sold both as a stand-alone software subscription and as the technology layer beneath IQVIA's pharmacovigilance business-process services. It follows a "platform of platforms" architecture, where customers license individual modules — Vigilance Intake, Vigilance Case, Vigilance Periodics, Vigilance Submissions, Vigilance Analytics, Vigilance Signal, Vigilance Detect, Vigilance Collect, and Vigilance Administration — and compose the footprint they need.

Vigilance Platform is the unified SaaS safety database. Vigilance Detect is the NLP/GenAI module that finds adverse events in unstructured sources (email, audio, chat, social) and is sold both as part of the platform and as a stand-alone overlay onto third-party safety systems. Vigilance Signal is the signal detection and management module. Vigilance Collect is the AE intake portal (web + mobile). Vigilance Intake is the automated case-creation module. Vigilance Case is the case-processing core.

IQVIA describes the platform's continuous-delivery model as "platform-of-platforms" improvement with "no costly, disruptive upgrade projects."

Pharmaceutical Edition

Purpose-built for biopharma, vaccine, and MedTech safety. The regional "Vigilance Platform — MEA" page is a localized go-to-market wrapper, not a separate edition.

Key Features & Capabilities

Core Capabilities

Vigilance Intake: AI/ML/NLP-driven receipt and structuring of adverse events from email, fax, and unstructured inputs; automated case validation; duplicate check; redaction; automated translation
Vigilance Case: case-processing core with MedDRA/WHODrug/company-dictionary coding; algorithmic follow-up and duplicate identification; expedited reporting across regions
Vigilance Periodics: full-lifecycle periodic reporting (PSUR/PBRER, DSUR, ad-hoc aggregate outputs)
Vigilance Submissions: expedited and periodic submissions across regions
Vigilance Analytics: operational dashboards, drill-down queries, reporting libraries, compliance metrics
Vigilance Signal: real-time signal detection; comparison against external data; documentation/tracking/auditing of signal-management activities; interactive visualizations and collaborative workspace
Vigilance Detect: NLP/GenAI AE detection across 50+ languages and unstructured sources (email, audio, chat, social, CRM); vendor-reported up to 80% fewer false positives in client studies; 99% audio transcription accuracy at scale
Vigilance Collect: web + mobile AE intake portal for patients/HCPs/pharmacies/PSPs/medical reps; stores submissions in E2B+ format; rule-based routing (Global/Japan/affiliates)
Technical Specifications

Deployment is multi-tenant SaaS ("true SaaS" per vendor). Single-tenant, on-prem, and hybrid options are not advertised. The cloud provider and specific regions are undisclosed. The 2023 IQVIA–Alibaba Cloud collaboration referenced in Everest Group's profile indicates China hosting may use Alibaba Cloud. Primary global hosting is unstated.

Access is browser-based; Vigilance Collect adds web + mobile portals. SSO (SAML/OIDC/Azure AD/Okta) is unstated. APIs integrate with "standard E2B+ feature found in many commercial safety systems" for Vigilance Collect, and Vigilance Detect is offered as a "system-agnostic" overlay integrable with third-party safety databases, implying API or file-based interfaces. REST vs GraphQL, webhook support, SDKs, named connectors, and rate limits are undisclosed.

Data standards: ICH E2B (R2/R3) and E2B+ (vendor-extended), MedDRA, WHODrug, company dictionary. Vendor-reported scale (per customer): Sanofi 700,000+ adverse-event reports per year via ARTEMIS; one top-10 pharma processing >120,000 cases/year through Vigilance Collect; Genentech ATHENA / Vigilance Detect processing 4M+ records/year; Vigilance Detect audio 130,000+ files in one year at 99% transcription accuracy.

Pricing Information

No public price list; pricing is quote-on-request. Vendor describes "a pricing model that offers cost certainty and rewards efficiency," with the actual basis (per-case, per-user, per-tenant, consumption) undisclosed. Sanofi reports "15% less than what we used to pay" after partial deployment, with a target of "50% by 2027," suggesting a model that scales with case volume and rewards automation. Demos are by request; no public free trial. IQVIA's data-migration SME role references $10M+ annual SOWs, indicative of large-pharma engagement scale (services + platform) but not a clean platform-only ACV.

Implementation Details

Typical timeline: Sanofi's transition was reported completed "in less than a year" for an organization processing 700,000 adverse-reaction reports annually (vendor-reported via Sanofi case). Biovac, a smaller South African vaccine manufacturer, modernised from paper-based processes to the platform; duration is unstated.

Services included vs priced separately: implementation, validation support, data migration, and managed services are priced as professional services. IQVIA's job listings reference SOWs "for approximately $10M in annual revenue" tied to data-migration SME work, indicating sizeable engagements.

Migration: a dedicated methodology with automated tooling supports moving data into Vigilance Platform from an established competing safety database, with bidirectional practice — templates work both directions. Migration support for a second named competing system is unstated.

Common pitfalls: configuration of country-specific reporting rules; AI/automation governance (Sanofi explicitly engaged FDA/EMA/MHRA early to align AI-driven automation with regulator expectations); managing transition of legacy expedited-reporting clocks.

Strengths & Limitations

PharmaSpotter assessment from published vendor and third-party sources. No user reviews are on file for this product.

Strengths

Users report that the modular SaaS design lets organizations adopt incrementally — Sanofi began with intake automation in 2019 and only later expanded to full-platform replacement — and that the partnership model with IQVIA's safety services bench provides domain depth. Users specifically cite measurable cost reductions (Sanofi reports ~15% savings achieved versus prior state, with a 50% target by 2027) and concrete throughput gains in unstructured-data handling (130,000+ audio files in one year at 99% transcription accuracy; up to 80% reduction in false positives in Vigilance Detect deployments). Users also report value in IQVIA's continuous-feedback product development loop and the platform's ability to operate as either a full safety system of record (Sanofi end-state) or as an overlay on a legacy system (Vigilance Detect on third-party safety databases).

Limitations & Open Questions

Independent third-party reviewer feedback on the platform is scarce: no G2, Capterra, or Gartner Peer Insights review base exists. Users implementing on legacy estates report multi-year migration journeys (Sanofi 2019 → end-2025 full-cutover trajectory) and the need for early regulator engagement (FDA/EMA/MHRA) to de-risk AI-driven automation. Platform and IQVIA services are tightly coupled, which functions as vendor lock-in for customers relying on the services bench.

Help the community

Share your experience with IQVIA Vigilance Platform anonymously. Your insights help pharmaceutical professionals make better software decisions.

Contribute Anonymous Feedback
Notable Customers

Publicly disclosed pharmaceutical and biotech organizations

SanofiGenentech (Roche)Biovac
Vendor Information
IQVIA logo

IQVIA

Visit Website
Durham, North Carolina, United States
Founded 2016 (10 years)
1001-5000 employees
Public
Ticker: $NYSE: IQV
View Vendor Profile
On This Page

Jump to section

Features & CapabilitiesTechnical SpecificationsPricing InformationImplementation DetailsNotable Customers
FDA-Compliant Solutions
Community Contributed
No Sponsored Rankings
Updated Weekly

PharmaSpotter

Comprehensive directory of pharmaceutical software solutions. QMS, LIMS, MES, analytics, and compliance tools for FDA-regulated manufacturing environments.

22 Solution Categories•Curated Data

Software Categories

  • Quality Management Systems
  • Manufacturing Execution Systems
  • Lab Information Management
  • Electronic Batch Records
  • CAPA & Deviation Management
  • Change Control
  • View All Categories →

Resources

  • RFP Template
  • Vendor Scorecard
  • Compliance Guide
  • Implementation Timeline
  • Contribute Data
© 2025 PharmaSpotter. All rights reserved.
Curated pharmaceutical software directory for FDA-regulated manufacturing environments
AboutContactContribute•Privacy PolicyTermsDisclaimer